Iodine-125 Seed Implantation in China: Evidence, Hospitals & Cost
Iodine-125 (I-125) seed implantation is permanent low-dose-rate interstitial brachytherapy: small radioactive sources are placed in or near selected tumor tissue to deliver radiation locally over time. China has substantial clinical and research activity in this technique, but the evidence and role differ sharply by cancer type, previous treatment, anatomy and treatment goal.
Quick answer: I-125 seed implantation is a local radiation technique, not a whole-body cancer treatment. China has expert consensus documents and disease-specific research in pancreatic cancer, lung cancer, recurrent cervical cancer and other selected tumors. A provider offering I-125 seeds must still explain why this technique is preferable to external-beam radiation, surgery, ablation or systemic treatment for the exact case.
✓ Brachytherapy ≠ systemic treatment
✓ Evidence separated by cancer type
✓ Provider claims separated from independent evidence
✓ No universal cure or success-rate claim
What Is Iodine-125 Seed Implantation?
I-125 seed implantation is a form of brachytherapy. Small radioactive seeds are implanted into or around a selected tumor under image guidance. The sources remain in place and deliver low-dose-rate radiation over time, concentrating dose near the target while limiting exposure with distance.
Internal radiation
Unlike external-beam radiation, the radioactive source is placed directly in or close to the tumor. Planning requires target definition, seed distribution and dose calculation.
Selected local control
The technique may be considered for selected primary, recurrent or metastatic local lesions when disease-specific evidence and anatomy support it.
Local treatment only
Implanted seeds treat the planned local volume. They do not automatically control cancer elsewhere in the body and do not replace systemic therapy when systemic disease requires it.
Where Does the Evidence Apply?
The safest way to interpret I-125 research is disease by disease. A result in recurrent cervical cancer or lung cancer cannot be transferred automatically to pancreatic, prostate or metastatic disease.
| Clinical setting | Evidence signal | How to interpret it | Status |
|---|---|---|---|
| Pancreatic cancer | Chinese expert consensus / guidelines plus ongoing 2026 review literature | China has a formal technical framework for selected permanent I-125 interstitial brachytherapy; this does not make it routine first-line treatment for every pancreatic cancer | China consensus |
| Lung cancer | 2024 review and 2025 China literature describe local use and combinations | Potential selected local-control role; standardization and comparative evidence remain important | Selected use |
| Pelvic recurrent cervical cancer after radiotherapy | 2024 single-arm meta-analysis: 6 studies, 246 Chinese patients | Signal for salvage/local treatment after prior radiotherapy, but based on non-randomized evidence | Salvage evidence |
| Other solid tumors / metastases | Broad Chinese clinical literature and expert consensus in selected sites | Eligibility is site-, dose-, anatomy- and prior-treatment-specific | Case-specific |
Evidence rule: response rate, local control, progression-free survival and overall survival are different endpoints. ParkMega keeps them separate rather than converting a local-response result into a general “success rate.”
Pancreatic Cancer: China Has a Formal I-125 Framework
Pancreatic cancer is one of the clearest examples of China-specific technical development around permanent I-125 seed implantation.
Indications and contraindications are meant to be standardized
The 2023-edition Chinese expert consensus, published in 2024, was created to standardize indications, contraindications, preparation, procedural technique, complications, efficacy evaluation and follow-up for permanent I-125 seed interstitial brachytherapy in pancreatic cancer.
Research remains active
A 2026 review from Shandong University researchers summarizes ongoing research progress in I-125 implantation for pancreatic cancer. That continuing research activity is not equivalent to universal standard-of-care status.
Important: pancreatic cancer treatment is stage- and resectability-driven. Local brachytherapy must be placed inside the broader plan for surgery, systemic therapy and/or external radiation rather than marketed as a standalone cure.
Lung Cancer and Recurrent Cervical Cancer: What Recent Evidence Shows
Promising local-treatment literature, with standardization gaps
A 2024 review describes I-125 implantation as a potentially useful option for local tumor management and combination treatment in lung cancer, while explicitly noting that standardized dose regimens and procedures are still needed.
Salvage signal after previous radiotherapy
A 2024 single-arm meta-analysis of six studies and 246 Chinese patients with pelvic recurrent cervical cancer after radiotherapy reported pooled objective response of 63%, disease control of 87%, median PFS of 9.09 months and median OS of 13.46 months, with grade ≥III adverse events of 6%.
Do not generalize those numbers. The cervical-cancer analysis concerns a specific salvage setting and is single-arm evidence. It is not an 87% cure rate and should not be applied to other cancers.
Who May Be Worth Reviewing for I-125 Brachytherapy?
Questions that make local brachytherapy relevant
- Is there a clearly defined local target that can be planned safely?
- Is surgery unsuitable, incomplete or not the preferred local option after specialist review?
- Has previous external-beam radiation limited additional external dose?
- Would local control or palliation meaningfully change management?
- Is there disease-specific evidence or consensus relevant to this exact setting?
Factors that can change eligibility
- Tumor size, shape, location and relationship to critical structures
- Previous surgery, radiation, ablation and systemic therapy
- Metastatic burden outside the planned seed field
- Bleeding, infection and procedural risks
- Ability to achieve an appropriate radiation dose distribution
This is not a self-eligibility checklist. The actual decision requires disease-specific oncology and brachytherapy planning.
I-125 Seeds vs External Radiation, Cryo, IRE and Thermal Ablation
These technologies solve different local-treatment problems. The correct comparison starts with disease and anatomy, not with which method sounds most advanced.
| Method | Mechanism | Potential role | Important limitation |
|---|---|---|---|
| I-125 seed implantation | Permanent low-dose-rate internal radiation | Selected local/recurrent tumors where interstitial dose delivery is appropriate | Requires dosimetric planning, implantation expertise and radiation-safety follow-up |
| External-beam RT / SBRT | External ionizing radiation | Standard or established local treatment in many cancers | Normal-tissue dose constraints and previous radiation matter |
| Cryoablation | Freeze–thaw tissue destruction | Selected lung, kidney, liver and other local targets | Probe placement and organ-specific complications |
| IRE / NanoKnife | Non-thermal electrical pulses | Selected anatomically difficult local tumors | Indication-specific evidence and cardiac/procedural precautions |
| Microwave / RFA | Thermal heating | Common local ablation approaches, especially liver/lung | Heat distribution, lesion size and nearby anatomy matter |
Decision rule: if a hospital proposes I-125 seeds, ask why interstitial brachytherapy is preferable to the standard local alternatives for this specific lesion and what evidence supports that choice.
China Provider Layer: Capability Is Not the Same as Eligibility
Fuda Cancer Hospital
FUDA publicly lists brachytherapy / iodine-125 seed implantation among its interventional oncology treatments. That supports provider capability, not a claim that every listed cancer is appropriate for the technique.
China has broader I-125 expertise
Chinese consensus documents involve specialists from multiple academic and oncology centers. For difficult cases, compare the proposed seed plan with disease-specific radiation oncology and interventional expertise rather than choosing solely by hospital marketing.
Confirm the actual team
Verify the treating department, named physician, current case acceptance, image-guidance method, treatment-planning system, seed activity/dose plan, inpatient requirements and international-patient pathway.
How Much Does Iodine-125 Seed Implantation Cost in China?
There is no reliable single China-wide price for I-125 implantation across cancers. Cost depends on the treatment plan, number of seeds, imaging guidance, anesthesia, hospital stay and whether the procedure is combined with another intervention.
Imaging + dosimetry
Pre-procedure imaging, target definition, treatment planning and dose calculation should be included or clearly itemized.
Seeds + guidance
The number and activity of seeds, needles, CT/ultrasound guidance and procedure complexity affect the quote.
Anesthesia + stay
Sedation/anesthesia, medicines, monitoring, room category and expected inpatient days should be specified.
Other cancer treatment
Chemotherapy, immunotherapy, embolization, external radiation or another local procedure may be separate from the seed-implantation quote.
Cost gate: ParkMega does not publish an unverified universal I-125 package price. The useful number is a written, itemized estimate based on imaging and a proposed treatment plan.
See Cancer Treatment Cost in China and, when relevant, FUDA Cancer Hospital Cost.
What to Send for an I-125 Seed Review
Minimum clinical packet
- Pathology report and exact diagnosis
- Current stage and known metastatic sites
- Recent contrast CT / MRI / PET-CT as appropriate
- DICOM imaging files when available
- Previous surgery, radiation, ablation and systemic treatment
- Relevant biomarkers, laboratory results and major comorbidities
Questions the center should answer
- Why I-125 rather than external radiation or another local treatment?
- What is the target volume and planned prescription dose?
- How many seeds are expected and how will placement be guided?
- What organs at risk limit the plan?
- What radiation-safety instructions apply after implantation?
- How will response and seed position be followed?
How ParkMega Handles an I-125 Case
Classify the disease
Diagnosis, stage, prior radiation, systemic disease and imaging determine whether an interstitial local-radiation question is relevant.
Match the evidence
We separate pancreatic, lung, recurrent cervical and other disease-specific evidence rather than using one universal brachytherapy claim.
Verify provider + plan
Only then do we verify current provider capability, international access and an itemized proposal based on the actual case.
Already have an I-125 proposal from China?
Send the diagnosis, imaging summary and proposed plan. We can structure the questions around evidence, alternatives, dose planning, provider verification and cost.
Questions to Ask Before Accepting I-125 Seed Implantation
Why this treatment?
Ask which disease-specific guideline, consensus or clinical evidence supports I-125 for this exact setting.
What dose is planned?
Ask for target volume, prescription dose, expected seed number/activity and how the plan will be checked after implantation.
Who performs it?
Confirm the named specialist, department, hospital campus and current experience with this cancer type.
What can go wrong?
Ask about bleeding, infection, seed migration/displacement, nearby-organ radiation injury and disease-specific procedural risks.
Why not EBRT, surgery or ablation?
The center should explain the alternatives and why interstitial brachytherapy is preferred in this anatomy and treatment sequence.
What is included?
Request planning, seeds, procedure, imaging, anesthesia, hospital stay, medicines, follow-up and major exclusions in writing.
Related China Cancer Guides
Frequently Asked Questions
Direct answers about iodine-125 seed implantation, evidence, hospitals, risks and costs in China.
What is iodine-125 seed implantation?
It is permanent low-dose-rate interstitial brachytherapy. Small radioactive I-125 sources are implanted in or near selected tumor tissue to deliver radiation locally over time.
Is iodine-125 seed implantation available in China?
Yes. China has substantial clinical activity, research and expert consensus work around I-125 seed implantation. Availability for an international patient still depends on the hospital, cancer type, imaging and current case acceptance.
Is I-125 implantation standard treatment for every cancer?
No. Its role is disease- and setting-specific. Some China literature and consensus documents address selected pancreatic, lung, recurrent cervical and other tumors, but that does not make I-125 a universal standard treatment.
Can iodine-125 seeds cure metastatic cancer?
I-125 implantation is a local treatment. It does not automatically treat cancer throughout the body and should not be presented as a universal cure for metastatic disease.
What evidence exists for pancreatic cancer?
China has a multidisciplinary expert consensus framework for permanent I-125 interstitial brachytherapy in pancreatic cancer covering indications, contraindications, technique, complications, evaluation and follow-up. Eligibility remains case-specific.
What evidence exists for recurrent cervical cancer?
A 2024 single-arm meta-analysis of six studies involving 246 Chinese patients with pelvic recurrence after radiotherapy reported response and survival outcomes suggesting a salvage-treatment signal. The evidence is non-randomized and applies to that specific setting.
Is I-125 better than external-beam radiation?
Not universally. Interstitial and external radiation have different dose distributions, indications and constraints. The correct choice depends on cancer type, previous radiation, anatomy and treatment goal.
What are the risks?
Risks depend on the implantation site and can include bleeding, infection, injury to nearby structures, radiation effects and seed displacement or migration. The treating team should explain patient-specific risks.
How much does I-125 seed implantation cost in China?
There is no single verified China-wide price. The quote depends on planning, number and activity of seeds, image guidance, anesthesia, hospital stay and any combined treatment.
What records should I send for review?
Usually pathology, stage, recent imaging and DICOM files, previous surgery/radiation/systemic therapy, relevant biomarkers and current laboratory results.
Sources and Evidence
- Current perspectives on iodine-125 seed implantation (2025). Bibliometric review of 2,212 publications, with China among the leading contributors. PMID 40459697.
- Pancreatic cancer expert consensus / guidelines. Chinese multidisciplinary framework for permanent I-125 seed interstitial brachytherapy. PMID 39206973.
- Pancreatic cancer research progress (2026). Current China review of I-125 seed implantation research. PMID 41633652.
- Lung cancer review (2024). Review of efficacy, safety and combination approaches; notes need for standardized dosing and procedures. PMID 39393163.
- Recurrent cervical cancer meta-analysis (2024). Six studies, 246 Chinese patients after previous radiotherapy. PMID 39158182.
- China consensus for recurrent soft-tissue carcinoma (2025). 3D-template-assisted CT-guided radioactive I-125 seed implantation. PMID 39928184.
Freshness note: physician schedules, seed programs, international access and prices can change. Verify the named provider, treatment plan and written quote before travel or payment.
Medical note: this page explains evidence and access. It does not diagnose cancer, recommend I-125 implantation for a specific patient, guarantee eligibility or replace specialist oncology/radiation-oncology advice.
Start With the Diagnosis and Imaging, Not the Technology
Send pathology, stage, recent imaging and previous treatment. The useful next step is to determine whether interstitial brachytherapy is a medically relevant question, which evidence applies, which China providers can review the case and what must be verified before travel.
✓ No cure claim✓ No automatic eligibility✓ Disease-specific evidence✓ Quote after treatment fit